Statin therapy and anthracycline-related cardiac dysfunction: a meta-analysis of randomized clinical trials

References

• Perez IE, Taveras Alam S, Hernandez GA, et al. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol. 2019;13:1179546819866445. doi: 10.1177/1179546819866445.
   Web of Science ®Google Scholar
• Hu W, Song M, Li L. Grading evaluation of cardiotoxicity in patients with breast cancer treated with adjuvant paclitaxel anthracycline/cyclophosphamide chemotherapy: a meta-analysis. Comput Math Methods Med. 2022;2022:7963146. doi: 10.1155/2022/7963146.
   PubMed Web of Science ®Google Scholar
• Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: cardioOncology state-of-the-art review. JACC CardioOncol. 2022; 4(1):19–37. doi: 10.1016/j.jaccao.2022.01.101.
   PubMedGoogle Scholar
• Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–1221. doi: 10.1200/JCO.2002.20.5.1215.
   PubMed Web of Science ®Google Scholar
• Bloom MW, Hamo CE, Cardinale D, et al. Cancer therapy-related cardiac dysfunction and heart failure part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. 2016;9(1):e002661. doi: 10.1161/CIRCHEARTFAILURE.115.002661.
   PubMed Web of Science ®Google Scholar
• Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14–25. doi: 10.1093/jnci/djp440.
   PubMedGoogle Scholar
• Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIβ–mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839–8846. doi: 10.1158/0008-5472.CAN-07-1649.
   PubMed Web of Science ®Google Scholar
• Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2x2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–1680. doi: 10.1093/eurheartj/ehw022.
   PubMed Web of Science ®Google Scholar
• Vila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Jr, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018;71(20):2281–2290. doi: 10.1016/j.jacc.2018.02.049.
   PubMed Web of Science ®Google Scholar
• Ayub-Ferreira SM, Avila M, Brandao S, et al. Carvedilol for prevention of chemotherapy induced cardiotoxicity: final results of the prospective, randomized, double-blind, placebo controlled CECCY trial. J Am Coll Cardiol. 2020;75(11):658. doi: 10.1016/S0735-1097(20)31285-7.
   Web of Science ®Google Scholar
• Cardinale D, Ciceri F, Latini R, et al. Anthracycline- induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International Cardio Oncology Society-one trial. Eur J Cancer. 2018;94:126–137. doi: 10.1016/j.ejca.2018.02.005.
   PubMed Web of Science ®Google Scholar
• Choudhary A, Rawat U, Kumar P, et al. Pleotropic effects of statins: the dilemma of wider utilization of statin. Egypt Heart J. 2023;75(1):1. doi: 10.1186/s43044-023-00327-8.
   PubMedGoogle Scholar
• Acar Z, Kale A, Turgut M, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58(9):988–989. doi: 10.1016/j.jacc.2011.05.025.
   PubMed Web of Science ®Google Scholar
• Nabati M, Janbabai G, Esmailian J, et al. Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial. J Cardiovasc Pharmacol Ther. 2019;24(3):233–241. doi: 10.1177/1074248418821721.
   PubMed Web of Science ®Google Scholar
• Hundley WG, D’Agostino R, Jr, Crotts T, et al. Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evid. 2022;1:10. doi: 10.1056/evidoa2200097.
   Google Scholar
• STOP-CA Trial: Statin Therapy Associated With Reduced Heart Dysfunction From Anthracyclines. 2023 scientific session of the American College of Cardiology. https://www.acc.org/latest-in-cardiology/articles/2023/03/01/22/45/sat-930am-stop-ca-acc-2023. (Accessed 03/13/2023).
   Google Scholar
• Arya S, Kaji AH, Boermeester MA. PRISMA reporting guidelines for meta-analyses and systematic reviews. JAMA Surg. 2021;156(8):789–790. doi: 10.1001/jamasurg.2021.0546.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savovi J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.
   PubMed Web of Science ®Google Scholar
• Viechtbauer W. Conducting meta-analyses in R with the metaphor package. J Stat Soft. 2010;36(3):1–48. doi: 10.18637/jss.v036.i03.
   Web of Science ®Google Scholar
• Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–4361. doi: 10.1093/eurheartj/ehac244.
   PubMed Web of Science ®Google Scholar
• Čelutkienė J, Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(9):1504–1524. doi: 10.1002/ejhf.1957.
   PubMed Web of Science ®Google Scholar
• Woźniak E, Broncel M, Niedzielski M, et al. The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells. PLoS One. 2023;18(2):e0280741. doi: 10.1371/journal.pone.0280741.
   PubMed Web of Science ®Google Scholar
• Koushki K, Shahbaz SK, Mashayekhi K, et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2021;60(2):175–199. doi: 10.1007/s12016-020-08791-9.
   PubMed Web of Science ®Google Scholar
• Pellikka PA, She L, Holly TA, et al. Variability in ejection fraction measured by echocardiography, gated single-photon emission computed tomography, and cardiac magnetic resonance in patients with coronary artery disease and left ventricular dysfunction. JAMA Netw Open. 2018;1(4):e181456. doi: 10.1001/jamanetworkopen.2018.1456.
   PubMed Web of Science ®Google Scholar
• Obasi M, Abovich A, Vo JB, et al. Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis. Cancer Causes Control. 2021;32(12):1407–1409. doi: 10.1007/s10552-021-01487-1.
   PubMed Web of Science ®Google Scholar